Literature DB >> 6135874

Hyperkalaemia in cyclosporin-treated renal allograft recipients.

D Adu, J Turney, J Michael, P McMaster.   

Abstract

Mean serum potassium levels were significantly higher for 9 months in renal allograft recipients receiving cyclosporin than in those receiving prednisolone and azathioprine. Sustained hyperkalaemia (serum potassium 6.0-7.1 mmol/l) inappropriate for their renal function (glomerular filtration rate 21-36 ml/min) developed in seven of forty-three cyclosporin-treated patients. All seven patients had hyperchloraemic acidosis; four were able to acidify their urine to pH less than or equal to 5.4. Six of the seven patients were hypertensive and receiving beta-blockers; one had had bilateral nephrectomy. Despite hyperkalaemia, plasma aldosterone levels were within the normal range in five patients and raised in two. During moderate sodium restriction, plasma renin activity was low or low-normal in five of the seven patients. In these patients a combination of hypoaldosteronism and renal tubular damage leading to a tubular defect of potassium and hydrogen ion secretion is the apparent cause of the hyperkalaemia and hyperchloraemic acidosis. Hyporeninaemia caused by beta-blockade probably blunts the aldosterone response to hyperkalaemia, thereby worsening it.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135874     DOI: 10.1016/s0140-6736(83)90345-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

1.  Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats.

Authors:  S Koehn; F J Frey; R F Speck; T Zeugin; T Schaffner; A Zimmermann; B M Frey
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

2.  American Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders.

Authors:  Mitchell H Rosner; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-29       Impact factor: 8.237

3.  Does the kind of immunosuppressive therapy influence plasma renin activity, aldosterone and vasopressin in patients with a kidney transplant?

Authors:  T Nieszporek; W Grzeszczak; F Kokot; E Zukovska-Szczechowska; A Wiecek; S Kusmierski; A Szkodny
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

Review 4.  Molecular diversity and regulation of renal potassium channels.

Authors:  Steven C Hebert; Gary Desir; Gerhard Giebisch; Wenhui Wang
Journal:  Physiol Rev       Date:  2005-01       Impact factor: 37.312

Review 5.  Cyclosporine and rheumatoid arthritis.

Authors:  O Førre; K Waalen; H E Rugstad; K J Berg; D Solbu; E Kåss
Journal:  Springer Semin Immunopathol       Date:  1988

6.  Influence of Tacrolimus on Depressive-Like Behavior in Diabetic Rats Through Brain-Derived Neurotrophic Factor Regulation in the Hippocampus.

Authors:  Yoo Jin Shin; Yeon Tae Chun; Sun Woo Lim; Kang Luo; Yi Quan; Sheng Cui; Eun Jeong Ko; Byung Ha Chung; Jiyeong Lee; Seongno Hong; Mun Yong Lee; Hee Gyoo Kang; Chul Woo Yang
Journal:  Neurotox Res       Date:  2019-06-14       Impact factor: 3.911

Review 7.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

8.  Isolated hyperkalemia associated with cyclosporine administration in allogeneic stem cell transplantation for renal cell carcinoma.

Authors:  Akiyoshi Takami; Hidesaku Asakura; Hiroyuki Takamatsu; Hirohito Yamazaki; Masahisa Arahata; Tomoe Hayashi; Masami Shibayama; Michiko Orito; Tomotaka Yoshida; Mikio Namiki; Shinji Nakao
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

Review 9.  Potassium and anaesthesia.

Authors:  J E Tetzlaff; J F O'Hara; M T Walsh
Journal:  Can J Anaesth       Date:  1993-03       Impact factor: 5.063

Review 10.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.